| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | inositol 1,4,5-trisphosphate-gated calcium channel activity | 1.49e-05 | 3 | 45 | 2 | GO:0005220 | |
| GeneOntologyCellularComponent | platelet dense tubular network membrane | 1.62e-04 | 9 | 45 | 2 | GO:0031095 | |
| GeneOntologyCellularComponent | platelet dense tubular network | 2.46e-04 | 11 | 45 | 2 | GO:0031094 | |
| GeneOntologyCellularComponent | myosin complex | 2.79e-04 | 59 | 45 | 3 | GO:0016459 | |
| Domain | InsP3_rcpt-bd | 1.62e-05 | 3 | 44 | 2 | IPR000493 | |
| Domain | RIH_assoc | 8.09e-05 | 6 | 44 | 2 | PF08454 | |
| Domain | RIH_assoc-dom | 8.09e-05 | 6 | 44 | 2 | IPR013662 | |
| Domain | RIH_dom | 8.09e-05 | 6 | 44 | 2 | IPR000699 | |
| Domain | Ins145_P3_rcpt | 8.09e-05 | 6 | 44 | 2 | IPR014821 | |
| Domain | Ryanodine_recept-rel | 8.09e-05 | 6 | 44 | 2 | IPR015925 | |
| Domain | - | 8.09e-05 | 6 | 44 | 2 | 1.25.10.30 | |
| Domain | RYDR_ITPR | 8.09e-05 | 6 | 44 | 2 | PF01365 | |
| Domain | Ins145_P3_rec | 8.09e-05 | 6 | 44 | 2 | PF08709 | |
| Domain | MIR | 2.41e-04 | 10 | 44 | 2 | PS50919 | |
| Domain | MIR | 2.41e-04 | 10 | 44 | 2 | PF02815 | |
| Domain | MIR | 2.41e-04 | 10 | 44 | 2 | SM00472 | |
| Domain | MIR_motif | 2.41e-04 | 10 | 44 | 2 | IPR016093 | |
| Domain | EGF_CA | 1.09e-03 | 86 | 44 | 3 | PF07645 | |
| Domain | EGF_Ca-bd_CS | 1.54e-03 | 97 | 44 | 3 | IPR018097 | |
| Domain | EGF_CA | 1.63e-03 | 99 | 44 | 3 | PS01187 | |
| Domain | ASX_HYDROXYL | 1.68e-03 | 100 | 44 | 3 | PS00010 | |
| Domain | EGF-type_Asp/Asn_hydroxyl_site | 1.99e-03 | 106 | 44 | 3 | IPR000152 | |
| Domain | EGF_3 | 2.24e-03 | 235 | 44 | 4 | PS50026 | |
| Domain | EGF-like_dom | 2.75e-03 | 249 | 44 | 4 | IPR000742 | |
| Domain | EGF_CA | 2.96e-03 | 122 | 44 | 3 | SM00179 | |
| Domain | EGF_1 | 3.00e-03 | 255 | 44 | 4 | PS00022 | |
| Domain | EGF-like_Ca-bd_dom | 3.10e-03 | 124 | 44 | 3 | IPR001881 | |
| Domain | Growth_fac_rcpt_ | 5.89e-03 | 156 | 44 | 3 | IPR009030 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_PRKN_TO_MGLUR1_SIGNALING_PATHWAY | 4.36e-05 | 5 | 30 | 2 | M49000 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_PLCD_ITPR_SIGNALING_PATHWAY | 6.53e-05 | 6 | 30 | 2 | M47960 | |
| Pathway | KEGG_MEDICUS_REFERENCE_BCR_PLCG_ITPR_SIGNALING_PATHWAY | 1.56e-04 | 9 | 30 | 2 | M47852 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SPTBN2_TO_MGLUR1_TRPC3_SIGNALING_PATHWAY | 1.95e-04 | 10 | 30 | 2 | M47661 | |
| Pathway | REACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS | 2.09e-04 | 140 | 30 | 4 | M27484 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_PRKCG_TO_MGLUR1_TRPC3_SIGNALING_PATHWAY | 2.38e-04 | 11 | 30 | 2 | M49033 | |
| Pathway | REACTOME_CLEC7A_DECTIN_1_INDUCES_NFAT_ACTIVATION | 2.38e-04 | 11 | 30 | 2 | M27466 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_PSEN1_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 3.37e-04 | 13 | 30 | 2 | M47696 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_SIGMAR1_TO_CA2_APOPTOTIC_PATHWAY | 3.37e-04 | 13 | 30 | 2 | M47751 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MGLUR1_TRPC3_SIGNALING_PATHWAY | 3.37e-04 | 13 | 30 | 2 | M47656 | |
| Pathway | REACTOME_ELEVATION_OF_CYTOSOLIC_CA2_LEVELS | 3.37e-04 | 13 | 30 | 2 | MM14553 | |
| Pathway | REACTOME_DEFECTIVE_GALNT3_CAUSES_HFTC | 5.16e-04 | 16 | 30 | 2 | M27410 | |
| Pathway | REACTOME_ELEVATION_OF_CYTOSOLIC_CA2_LEVELS | 5.16e-04 | 16 | 30 | 2 | M26945 | |
| Pathway | KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM | 5.51e-04 | 76 | 30 | 3 | M9052 | |
| Pathway | REACTOME_DEFECTIVE_C1GALT1C1_CAUSES_TNPS | 5.84e-04 | 17 | 30 | 2 | M27412 | |
| Pathway | REACTOME_VEGFR2_MEDIATED_CELL_PROLIFERATION | 7.32e-04 | 19 | 30 | 2 | M27423 | |
| Pathway | KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 7.32e-04 | 19 | 30 | 2 | M47760 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TCR_PLCG_ITPR_SIGNALING_PATHWAY | 7.32e-04 | 19 | 30 | 2 | M47733 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MACHR_CA2_APOPTOTIC_PATHWAY | 8.12e-04 | 20 | 30 | 2 | M47688 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_MACHR_CA2_APOPTOTIC_PATHWAY | 8.97e-04 | 21 | 30 | 2 | M47689 | |
| Pathway | REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS | 8.97e-04 | 21 | 30 | 2 | MM15706 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 9.85e-04 | 22 | 30 | 2 | M47690 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MGLUR5_CA2_APOPTOTIC_PATHWAY | 9.85e-04 | 22 | 30 | 2 | M47675 | |
| Pathway | REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS | 1.08e-03 | 23 | 30 | 2 | M556 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 1.08e-03 | 23 | 30 | 2 | M47676 | |
| Pathway | REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS | 1.27e-03 | 25 | 30 | 2 | MM14511 | |
| Pathway | REACTOME_DECTIN_2_FAMILY | 1.38e-03 | 26 | 30 | 2 | M27483 | |
| Pathway | REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS | 1.49e-03 | 27 | 30 | 2 | M12123 | |
| Pathway | REACTOME_PLATELET_CALCIUM_HOMEOSTASIS | 1.49e-03 | 27 | 30 | 2 | MM15053 | |
| Pathway | REACTOME_PLATELET_CALCIUM_HOMEOSTASIS | 1.60e-03 | 28 | 30 | 2 | M924 | |
| Pathway | WP_NUCLEAR_RECEPTORS_IN_LIPID_METABOLISM_AND_TOXICITY | 1.84e-03 | 30 | 30 | 2 | MM15866 | |
| Pathway | WP_EFFECT_OF_OMEGA3_PUFA_ON_HUNTINGTONS_DISEASE_PATHWAYS | 2.02e-03 | 119 | 30 | 3 | M48309 | |
| Pathway | REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX | 2.09e-03 | 32 | 30 | 2 | MM15368 | |
| Pathway | REACTOME_GLUCAGON_LIKE_PEPTIDE_1_GLP1_REGULATES_INSULIN_SECRETION | 2.09e-03 | 32 | 30 | 2 | MM14983 | |
| Pathway | BIOCARTA_NUCLEARRS_PATHWAY | 2.22e-03 | 33 | 30 | 2 | MM1448 | |
| Pathway | REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX | 2.22e-03 | 33 | 30 | 2 | M9694 | |
| Pathway | BIOCARTA_NUCLEARRS_PATHWAY | 2.35e-03 | 34 | 30 | 2 | M16393 | |
| Pathway | WP_NUCLEAR_RECEPTORS_IN_LIPID_METABOLISM_AND_TOXICITY | 2.49e-03 | 35 | 30 | 2 | M39488 | |
| Pathway | SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES | 2.64e-03 | 36 | 30 | 2 | M1315 | |
| Pathway | WP_VITAMIN_DSENSITIVE_CALCIUM_SIGNALING_IN_DEPRESSION | 2.64e-03 | 36 | 30 | 2 | M39831 | |
| Pathway | REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS | 2.64e-03 | 36 | 30 | 2 | MM14687 | |
| Pathway | REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS | 2.78e-03 | 37 | 30 | 2 | M11153 | |
| Pathway | PID_ATR_PATHWAY | 3.09e-03 | 39 | 30 | 2 | M46 | |
| Pathway | REACTOME_DISEASES_OF_GLYCOSYLATION | 3.40e-03 | 143 | 30 | 3 | M27275 | |
| Pathway | REACTOME_DAG_AND_IP3_SIGNALING | 3.41e-03 | 41 | 30 | 2 | M512 | |
| Pathway | WP_2Q37_COPY_NUMBER_VARIATION_SYNDROME | 3.53e-03 | 145 | 30 | 3 | M45512 | |
| Pathway | WP_DNA_REPLICATION | 3.58e-03 | 42 | 30 | 2 | M39335 | |
| Pathway | REACTOME_GLUCAGON_LIKE_PEPTIDE_1_GLP1_REGULATES_INSULIN_SECRETION | 3.58e-03 | 42 | 30 | 2 | M791 | |
| Pathway | WP_RENINANGIOTENSINALDOSTERONE_SYSTEM_RAAS | 3.92e-03 | 44 | 30 | 2 | M39845 | |
| Pathway | SIG_CHEMOTAXIS | 4.09e-03 | 45 | 30 | 2 | M5193 | |
| Pathway | SIG_BCR_SIGNALING_PATHWAY | 4.28e-03 | 46 | 30 | 2 | M8626 | |
| Pubmed | PAD2-mediated citrullination of Fibulin-5 promotes elastogenesis. | 1.71e-06 | 2 | 46 | 2 | 34274450 | |
| Pubmed | Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor. | 1.71e-06 | 2 | 46 | 2 | 8663526 | |
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 21685325 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 15890645 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 18848467 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 32401676 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 20813840 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 7559486 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 21815153 | ||
| Pubmed | Role of mucins in the skin during benign and malignant conditions. | 1.71e-06 | 2 | 46 | 2 | 21146919 | |
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 20843799 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 20953890 | ||
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 32400877 | ||
| Pubmed | Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients. | 1.71e-06 | 2 | 46 | 2 | 32776556 | |
| Pubmed | 1.71e-06 | 2 | 46 | 2 | 1374893 | ||
| Pubmed | Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues. | 1.71e-06 | 2 | 46 | 2 | 29408556 | |
| Pubmed | Distinct roles of inositol 1,4,5-trisphosphate receptor types 1 and 3 in Ca2+ signaling. | 1.71e-06 | 2 | 46 | 2 | 14707143 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 31979185 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 10874040 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 9808793 | ||
| Pubmed | Tsg101 regulates PI(4,5)P2/Ca(2+) signaling for HIV-1 Gag assembly. | 5.13e-06 | 3 | 46 | 2 | 24904548 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 12421829 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 20395455 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 17327232 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 19924550 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 22992961 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 17437169 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 16014380 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 18194433 | ||
| Pubmed | Expression of aberrant mucins in lobular carcinoma with histiocytoid feature of the breast. | 5.13e-06 | 3 | 46 | 2 | 17333267 | |
| Pubmed | Mucin expression in reactive gastropathy: an immunohistochemical analysis. | 5.13e-06 | 3 | 46 | 2 | 17227128 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 17890015 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 18547250 | ||
| Pubmed | Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma. | 5.13e-06 | 3 | 46 | 2 | 34969769 | |
| Pubmed | Differences in the expression of mucins in various forms of cystitis glandularis. | 5.13e-06 | 3 | 46 | 2 | 17659847 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 35185017 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 36350267 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 12032348 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 18250332 | ||
| Pubmed | IP3 receptors regulate vascular smooth muscle contractility and hypertension. | 5.13e-06 | 3 | 46 | 2 | 27777977 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 11413485 | ||
| Pubmed | Inositol 1, 4, 5-trisphosphate receptors and human left ventricular myocytes. | 5.13e-06 | 3 | 46 | 2 | 23983250 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 12652076 | ||
| Pubmed | Differential distribution of inositol trisphosphate receptor isoforms in mouse oocytes. | 5.13e-06 | 3 | 46 | 2 | 9858485 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 26009177 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 24920497 | ||
| Pubmed | Differential inositol 1,4,5-trisphosphate receptor signaling in a neuronal cell line. | 5.13e-06 | 3 | 46 | 2 | 17581770 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 20427533 | ||
| Pubmed | Predominant role of type 1 IP3 receptor in aortic vascular muscle contraction. | 5.13e-06 | 3 | 46 | 2 | 18241669 | |
| Pubmed | Receptor-activated single channels in intact human platelets. | 5.13e-06 | 3 | 46 | 2 | 1693919 | |
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 19068129 | ||
| Pubmed | 5.13e-06 | 3 | 46 | 2 | 23955339 | ||
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 25215520 | ||
| Pubmed | Regulation of InsP3 receptor activity by neuronal Ca2+-binding proteins. | 1.03e-05 | 4 | 46 | 2 | 14685260 | |
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 33154304 | ||
| Pubmed | Inositol 1, 4, 5-trisphosphate receptor interacts with the SNARE domain of syntaxin 1B. | 1.03e-05 | 4 | 46 | 2 | 21424589 | |
| Pubmed | Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. | 1.03e-05 | 4 | 46 | 2 | 24603585 | |
| Pubmed | Gastric mucin expression in first-degree relatives of gastric cancer patients. | 1.03e-05 | 4 | 46 | 2 | 24901817 | |
| Pubmed | MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. | 1.03e-05 | 4 | 46 | 2 | 27298226 | |
| Pubmed | Ins(1,4,5)P3 receptor-mediated Ca2+ signaling and autophagy induction are interrelated. | 1.03e-05 | 4 | 46 | 2 | 22082873 | |
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 25638393 | ||
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 36367122 | ||
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 28419336 | ||
| Pubmed | Expression of MUC1, MUC2, MUC5AC and MUC5B in mucinous lesions of the breast. | 1.03e-05 | 4 | 46 | 2 | 22269464 | |
| Pubmed | Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus. | 1.03e-05 | 4 | 46 | 2 | 17401217 | |
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 11163362 | ||
| Pubmed | IP3R-mediated Ca2+ signaling controls B cell proliferation through metabolic reprogramming. | 1.03e-05 | 4 | 46 | 2 | 35494252 | |
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 28615414 | ||
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 11524429 | ||
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 10828023 | ||
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 23884412 | ||
| Pubmed | [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors]. | 1.03e-05 | 4 | 46 | 2 | 17991319 | |
| Pubmed | 1.03e-05 | 4 | 46 | 2 | 25298197 | ||
| Pubmed | Mucins in neoplastic spectrum of colorectal polyps: can they provide predictions? | 1.03e-05 | 4 | 46 | 2 | 20929551 | |
| Pubmed | Polymorphism of human mucin genes in chest disease: possible significance of MUC2. | 1.71e-05 | 5 | 46 | 2 | 11062147 | |
| Pubmed | Differential expression of MUC genes in endometrial and cervical tissues and tumors. | 1.71e-05 | 5 | 46 | 2 | 16188033 | |
| Pubmed | InsP₃receptors and Orai channels in pancreatic acinar cells: co-localization and its consequences. | 1.71e-05 | 5 | 46 | 2 | 21568942 | |
| Pubmed | 1.71e-05 | 5 | 46 | 2 | 19706527 | ||
| Pubmed | 1.71e-05 | 5 | 46 | 2 | 12135769 | ||
| Pubmed | 1.71e-05 | 5 | 46 | 2 | 8081710 | ||
| Pubmed | MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. | 1.71e-05 | 5 | 46 | 2 | 16475027 | |
| Pubmed | 1.71e-05 | 5 | 46 | 2 | 15613488 | ||
| Pubmed | 2.56e-05 | 6 | 46 | 2 | 23463619 | ||
| Pubmed | Sprouty2 regulates PI(4,5)P2/Ca2+ signaling and HIV-1 Gag release. | 2.56e-05 | 6 | 46 | 2 | 21762810 | |
| Pubmed | IP3Rs are sufficient for dendritic cell Ca2+ signaling in the absence of RyR1. | 2.56e-05 | 6 | 46 | 2 | 16844763 | |
| Pubmed | 2.56e-05 | 6 | 46 | 2 | 20519450 | ||
| Pubmed | Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging. | 2.56e-05 | 6 | 46 | 2 | 25966694 | |
| Pubmed | Myosin-I isozymes in neonatal rodent auditory and vestibular epithelia. | 2.56e-05 | 6 | 46 | 2 | 12486594 | |
| Pubmed | Genetic evidence supporting caveolae microdomain regulation of calcium entry in endothelial cells. | 2.56e-05 | 6 | 46 | 2 | 17416589 | |
| Pubmed | 3.58e-05 | 7 | 46 | 2 | 11860456 | ||
| Pubmed | Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes. | 3.58e-05 | 7 | 46 | 2 | 22495310 | |
| Pubmed | 6.12e-05 | 9 | 46 | 2 | 15623527 | ||
| Pubmed | 6.12e-05 | 9 | 46 | 2 | 25737585 | ||
| Pubmed | GINS complex protein Sld5 recruits SIK1 to activate MCM helicase during DNA replication. | 7.65e-05 | 10 | 46 | 2 | 27592030 | |
| Pubmed | Type 1 and 3 inositol trisphosphate receptors are required for extra-embryonic vascular development. | 9.34e-05 | 11 | 46 | 2 | 27514653 | |
| Pubmed | 1.12e-04 | 12 | 46 | 2 | 18558092 | ||
| Pubmed | 1.54e-04 | 14 | 46 | 2 | 34630045 | ||
| Pubmed | Inositol 1,4,5-trisphosphate receptors are essential for the development of the second heart field. | 1.54e-04 | 14 | 46 | 2 | 21382375 | |
| Pubmed | Synergistic Signaling by Light and Acetylcholine in Mouse Iris Sphincter Muscle. | 1.78e-04 | 15 | 46 | 2 | 28578927 | |
| Pubmed | 2.24e-04 | 660 | 46 | 6 | 32780723 | ||
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q37 | 1.53e-03 | 226 | 46 | 3 | chr2q37 | |
| Cytoband | 2q37.3 | 2.74e-03 | 77 | 46 | 2 | 2q37.3 | |
| GeneFamily | Inositol 1,4,5-triphosphate receptors|Protein phosphatase 1 regulatory subunits | 9.09e-06 | 3 | 32 | 2 | 297 | |
| GeneFamily | Myosins, class I | 8.44e-05 | 8 | 32 | 2 | 1097 | |
| GeneFamily | Armadillo repeat containing|Protein phosphatase 1 regulatory subunits | 2.81e-04 | 181 | 32 | 4 | 694 | |
| GeneFamily | CD molecules|Mucins | 6.24e-04 | 21 | 32 | 2 | 648 | |
| ToppCell | Parenchymal-NucSeq-Epithelial-Epi_submucosal-gland-Myoepithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.86e-06 | 198 | 46 | 5 | 24bc53bd8ef8f4f2f4fc377aeee75126ad5d311f | |
| ToppCell | facs-GAT-Fat-18m-Lymphocytic-NK_cell|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.18e-05 | 159 | 46 | 4 | 796e63f6052189106359a4e01eae3e466bf1d593 | |
| ToppCell | TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Tubular-6|TCGA-Stomach / Sample_Type by Project: Shred V9 | 2.18e-05 | 159 | 46 | 4 | 655c0749c238bd68cb797adb83e25a23b8a3cc9d | |
| ToppCell | P07-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.29e-05 | 161 | 46 | 4 | b19f82dd98a3064581793711bb70373f18abecd9 | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.25e-05 | 176 | 46 | 4 | cb8fd56a4f935cdda19d7ab43382cdda7c307667 | |
| ToppCell | Club_cells-SSc-ILD_01|World / lung cells shred on cell class, cell subclass, sample id | 3.39e-05 | 178 | 46 | 4 | be64d4be23fb96a4cdd7980c58880fdfe817747f | |
| ToppCell | RA-13._Vascular_Smooth_Muscle|RA / Chamber and Cluster_Paper | 3.78e-05 | 183 | 46 | 4 | 818fd886e0188091310825f9145fa53328f2c979 | |
| ToppCell | 356C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-|356C / Donor, Lineage, Cell class and subclass (all cells) | 4.03e-05 | 186 | 46 | 4 | 189b75aa98903f1cb65b624524ba6c30df7e42ff | |
| ToppCell | 356C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)|356C / Donor, Lineage, Cell class and subclass (all cells) | 4.03e-05 | 186 | 46 | 4 | 261891d0b148e285339ae0b9e36136ceabd9b6f5 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.1.3|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.11e-05 | 187 | 46 | 4 | 7c44cec1c26ca5907a495f2d7e633410e2e9728f | |
| ToppCell | LA-13._Vascular_Smooth_Muscle|LA / Chamber and Cluster_Paper | 4.20e-05 | 188 | 46 | 4 | 34e1b074a3995aa46ab194eb45115d76d1a5514d | |
| ToppCell | PND07-28-samps-Mesenchymal-Matrix_fibroblast|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 4.29e-05 | 189 | 46 | 4 | dc5164591dea45b420798b94dda211be03daa70c | |
| ToppCell | PND07-28-samps-Mesenchymal-Matrix_fibroblast-FB-3|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 4.38e-05 | 190 | 46 | 4 | 1196b8ea2c44c7c80f5ee589dd517e6a413f2077 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.1.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.47e-05 | 191 | 46 | 4 | 6cb2c107bc674aa173b4009f320a1687a76f3979 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.4.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.47e-05 | 191 | 46 | 4 | f00d6824bd138b192a996e9f7de57b235bb24c18 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.0.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.65e-05 | 193 | 46 | 4 | 8646e573f2d2ff175f3d02bfdf214e65f3b614d3 | |
| ToppCell | PND07-28-samps-Mesenchymal|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 4.75e-05 | 194 | 46 | 4 | 68bcc1fe8dc8d5f23a12154fc9b41362fdef0b1d | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.84e-05 | 195 | 46 | 4 | 3e24570def013d5b0b1ef1d7a5ced7dfd922590b | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.84e-05 | 195 | 46 | 4 | 6617abca0009ad3d8731f515f91ab275f9ea4c40 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.84e-05 | 195 | 46 | 4 | fc0ae145a2118df7cbbc9ac4ca9dc12d26c087c4 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.84e-05 | 195 | 46 | 4 | eec187c087e432417bc346c5d3ead72f58bf3215 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.1.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.94e-05 | 196 | 46 | 4 | b1abecc0aafc09ca70a5fde624f2a998c4aa3341 | |
| ToppCell | cellseq-Epithelial-Epithelial_Alveolar|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 4.94e-05 | 196 | 46 | 4 | a7cbe66ebd8931ef2b8ff26a42afce0ad1c48f17 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.94e-05 | 196 | 46 | 4 | 7e5addaa844e66f8160e05858c341866a80aed23 | |
| ToppCell | ASK440-Epithelial-Type_2|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq | 4.94e-05 | 196 | 46 | 4 | 754b4202b617165c6994a0b5a9b1e486dccdd44d | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.94e-05 | 196 | 46 | 4 | 2b36b9a40fe415917afccff99ad9c3474e087d0d | |
| ToppCell | Control_saline-Epithelial_alveolar-AT_2-Differentiating_AT2|Control_saline / Treatment groups by lineage, cell group, cell type | 5.04e-05 | 197 | 46 | 4 | 44a59dfb889577b3160a5b13ada1276771a00241 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.04e-05 | 197 | 46 | 4 | d6c9da7a3a6d2bcb13e2fc6605c8a59e7fb121c5 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 5.04e-05 | 197 | 46 | 4 | 80e153790cef37b743e22a7370ff5b3a6abf147d | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.04e-05 | 197 | 46 | 4 | bf10727fbe90b71d2ac60a11711e5f0701b3799d | |
| ToppCell | droplet-Mammary_Gland-nan-18m-Epithelial-luminal_progenitor_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.04e-05 | 197 | 46 | 4 | ed3a37f532741764060d297a560eeeeec279d9c4 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.04e-05 | 197 | 46 | 4 | 80b05c8ad9c1edc5dea3236079372475431343fe | |
| ToppCell | Biopsy_Control_(H.)-Epithelial-AT2|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 5.24e-05 | 199 | 46 | 4 | 5323d49d3be980605b3e609b7f03bddba6e50e8a | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.24e-05 | 199 | 46 | 4 | 2dc33804f6691d7c9682e6c9b885e945fb97fc36 | |
| ToppCell | Epithelial_cells|World / lung cells shred on cell class, cell subclass, sample id | 5.24e-05 | 199 | 46 | 4 | bbe69e44b7970f57628365ae771790f2b13d0cae | |
| ToppCell | Biopsy_IPF-Epithelial-AT2|Biopsy_IPF / Sample group, Lineage and Cell type | 5.24e-05 | 199 | 46 | 4 | c841d475703d3489161fb7904526bd7563d5fb0f | |
| ToppCell | Bronchial-10x5prime-Epithelial-Epi_alveolar-AT2|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.34e-05 | 200 | 46 | 4 | b535323e18d9fb0dde1e0026df142c831e48c29f | |
| ToppCell | Parenchyma_Control_(B.)-Epithelial-TX-AT2-2|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 5.34e-05 | 200 | 46 | 4 | 35c05cae30cd6b323d2662f1396ddeab08bc75fc | |
| ToppCell | Lung_Parenchyma-Control-Epithelial-Epithelial-AT2-2-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.34e-05 | 200 | 46 | 4 | 3c251ad03fbbdae91dfd9037880ba43adbb03807 | |
| ToppCell | Lung_Parenchyma-Control-Epithelial-Epithelial-AT2-2|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.34e-05 | 200 | 46 | 4 | c905451425d1c24773bb0ca69bcf0309b277d2f1 | |
| ToppCell | Lung_Parenchyma-Control-Epithelial-Epithelial-AT2-1-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.34e-05 | 200 | 46 | 4 | 65c83a3f6ee2a10bcb5b95076696232c6373a7b4 | |
| ToppCell | Lung_Parenchyma-Control-Epithelial-Epithelial-AT2-1|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.34e-05 | 200 | 46 | 4 | 40e969883bc302e8fbc6b6ab9814529dc1472902 | |
| ToppCell | Lung_Parenchyma-Severe-Epithelial-Epithelial-AT2-2-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.34e-05 | 200 | 46 | 4 | eb44d1f80ecaac3a022cd04ab16dc36151e45488 | |
| ToppCell | Parenchyma_Control_(B.)-Epithelial-TX-AT2-1|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 5.34e-05 | 200 | 46 | 4 | ad9cdc82a647d379abc713a56db0e11bb6494106 | |
| ToppCell | Lung_Parenchyma-Severe-Epithelial-Epithelial-AT2-2|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 5.34e-05 | 200 | 46 | 4 | acc771a902cf2f060c3eb9aedb72a256f5778a6c | |
| ToppCell | Parenchyma_COVID-19-Epithelial-TX-AT2-2|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 5.34e-05 | 200 | 46 | 4 | ceb613ac6cdf0e3e6bb3f04d89034e18a524cefb | |
| ToppCell | Epithelial-B_(AT1-AT2-progenitors)|World / shred on cell class and cell subclass (v4) | 4.59e-04 | 146 | 46 | 3 | 4511916904c1fac252cb68e871b782207f8137b3 | |
| ToppCell | lung-Type_II_Pneumocytes|lung / shred on tissue and cell subclass | 4.68e-04 | 147 | 46 | 3 | 8a3039de45b8087f8319e2e37329acf7278219b7 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_D|NK_cells / Donor, Lineage, Cell class and subclass (all cells) | 4.77e-04 | 148 | 46 | 3 | 10dcbdb47cac908648d9d652c8095b536db19b8a | |
| ToppCell | Int-URO-Lymphocyte-T_NK-CD8_Naive|Int-URO / Disease, Lineage and Cell Type | 5.16e-04 | 152 | 46 | 3 | 52d6f9cf1f4637c922f582705d625b4cbe3dc0c2 | |
| ToppCell | facs-MAT-Fat-24m-Lymphocytic-NK_cell|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.16e-04 | 152 | 46 | 3 | fa03262e2853b7d35ef8cdbb652930abad90563c | |
| ToppCell | facs-Lung-EPCAM-3m-Lymphocytic-NK_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.26e-04 | 153 | 46 | 3 | 2a94092937267cd2282452dfde3d328d763d4294 | |
| ToppCell | Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 5.26e-04 | 153 | 46 | 3 | 88ca2d2c2ab19fbee13e18951b993ee05dd30f67 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.26e-04 | 153 | 46 | 3 | d8773ee16c7d3e0834b9f64054d42336d6f9833b | |
| ToppCell | Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)-|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 5.26e-04 | 153 | 46 | 3 | 553dff9688a1996d8f4ba16e60c683593d781389 | |
| ToppCell | facs-Lung-EPCAM-3m-Lymphocytic-Natural_Killer|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.26e-04 | 153 | 46 | 3 | ad33c81fe6ac10e7c263d42541aae0d796923bad | |
| ToppCell | Children_(3_yrs)-Mesenchymal-chondrocyte-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.56e-04 | 156 | 46 | 3 | 60f1ce38e34b582f589db1e0d6139282c1902b2b | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.67e-04 | 157 | 46 | 3 | 9665a1375cfd8e9b8781c852686591226c0e0d9a | |
| ToppCell | facs-MAT-Fat-18m-Lymphocytic-NK_cell|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.67e-04 | 157 | 46 | 3 | e6846ffd1bb18bf0469bc6d49ab6cf3533d9cde6 | |
| ToppCell | facs-SCAT-Fat-24m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.67e-04 | 157 | 46 | 3 | ad8c6eb34f5288288c4066119c17325afefbaafc | |
| ToppCell | 3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.88e-04 | 159 | 46 | 3 | 60b1f4dce2ce0911160fda17f137c064da31e2eb | |
| ToppCell | facs-Lung-18m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell-natural_killer|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.99e-04 | 160 | 46 | 3 | e4516b093003275084fc327d1597394a436754eb | |
| ToppCell | droplet-Liver-HEPATOCYTES-1m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.99e-04 | 160 | 46 | 3 | a494001b1f6dec33624f98fa3c24bad6988d0425 | |
| ToppCell | facs-Lung-18m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.99e-04 | 160 | 46 | 3 | 0a507e3d59d7f744d0201a531ea84fa97a68aedb | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-AT1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.10e-04 | 161 | 46 | 3 | 1e17a993126e1f2a25ee7dfbb95a74ccb2a26791 | |
| ToppCell | Adult-Mesenchymal-myofibroblast_cell-D175|Adult / Lineage, Cell type, age group and donor | 6.10e-04 | 161 | 46 | 3 | 048b7dc00746987a24bf870d4d278c4183eb04a2 | |
| ToppCell | droplet-Lung-30m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.10e-04 | 161 | 46 | 3 | cd4a736d0cec31477c6e8d3b07a04ede1559854b | |
| ToppCell | droplet-Lung-30m-Hematologic-Lymphocytic_NK_ILC|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.10e-04 | 161 | 46 | 3 | 28930ba576625b98cc15993d1499e9dc5edbb5a9 | |
| ToppCell | E16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.21e-04 | 162 | 46 | 3 | 34b4cd3d2258f88dfbd6d32abd1db87aff8a6b6f | |
| ToppCell | droplet-Lung-nan-18m-Lymphocytic-Natural_Killer|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.21e-04 | 162 | 46 | 3 | 66069146e2666d13c594bd76247893354a697c5d | |
| ToppCell | droplet-Lung-nan-3m-Lymphocytic-NK_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.21e-04 | 162 | 46 | 3 | 4b490989005bb03d4e7bbea01580f8548eff150f | |
| ToppCell | droplet-Lung-nan-3m-Lymphocytic-Natural_Killer|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.21e-04 | 162 | 46 | 3 | e4a09bf1a51710f6c57e6e01edf8b4619459d96d | |
| ToppCell | E16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1-AT1_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.32e-04 | 163 | 46 | 3 | 56b8668dbf06faa6866ec71f29b92907b73f074d | |
| ToppCell | droplet-Lung-nan-18m-Lymphocytic-NK_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.32e-04 | 163 | 46 | 3 | 801163c05f8fdacaebd0cb9b4c92741276bfa3e3 | |
| ToppCell | facs-Spleen-nan-3m-Lymphocytic-NK_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.43e-04 | 164 | 46 | 3 | a187bd5beca017ef657ef07c006e7f94ea3b911b | |
| ToppCell | droplet-Lung-18m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell-natural_killer|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.43e-04 | 164 | 46 | 3 | c2cd4e4b88cc1b80a9494f59d31339007ff824c1 | |
| ToppCell | droplet-Lung-18m-Hematologic-Lymphocytic_NK_ILC-natural_killer_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.43e-04 | 164 | 46 | 3 | d4d08353c7322f97ea07dd583b08661d635fff20 | |
| ToppCell | PND14-Epithelial-Epithelial_Airway-Neurosecretory-Secretory-Secretory_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.55e-04 | 165 | 46 | 3 | baff639a7046fb5cacb70f341b6d24cef3519f8e | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Lymphocytic-NK_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.55e-04 | 165 | 46 | 3 | 93ed399b8c6278e5f1528c07758fb502d80a1a8b | |
| ToppCell | droplet-Lung-18m-Hematologic-Lymphocytic_NK_ILC|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.55e-04 | 165 | 46 | 3 | 88745bf7ecb0f7fc93077cea20171d40535dd56b | |
| ToppCell | PND14-Epithelial-Epithelial_Airway-Neurosecretory|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.55e-04 | 165 | 46 | 3 | 6fdce8b23736409a23884ef3918638ffc067a86f | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Lymphocytic-Natural_Killer|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.55e-04 | 165 | 46 | 3 | 80f82aaab48791cb06fcb2d8ed7821f162742385 | |
| ToppCell | droplet-Liver-LIVER-NPC-1m-Lymphocytic-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.55e-04 | 165 | 46 | 3 | 8c7a6f9e2ca0ce077426d3d0726e3f5a4c03b296 | |
| ToppCell | facs-Kidney-nan-3m-Lymphocytic|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.55e-04 | 165 | 46 | 3 | ba041deb0d9c187f251493ccd4794b5f09abd5aa | |
| ToppCell | PND14-Epithelial-Epithelial_Airway-Neurosecretory-Secretory|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.55e-04 | 165 | 46 | 3 | dd4d36ff8efb89fee1fb4c48d1b8f46902119909 | |
| ToppCell | 343B-Myeloid-Macrophage-FABP4+_Macrophage|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 6.66e-04 | 166 | 46 | 3 | f62db9d9b6c9dd8f2afcaea0fc5f8c69f50205b2 | |
| ToppCell | facs-Lung-nan-3m-Myeloid-myeloid_dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.66e-04 | 166 | 46 | 3 | 5c132f505dc5f699c87913f140344fc9f8e7e0f5 | |
| ToppCell | facs-Marrow-B-cells-24m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.66e-04 | 166 | 46 | 3 | 13027ae342994db4540e64eb910df1f42b160931 | |
| ToppCell | facs-Marrow-B-cells-24m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.66e-04 | 166 | 46 | 3 | b21e45bd43f26149b9cd6e45c19241c82d54fb2f | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Lymphocytic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.66e-04 | 166 | 46 | 3 | 3213466380becf0ee3d4d9a0776ccbb1ee4eccea | |
| ToppCell | facs-Spleen-nan-3m-Lymphocytic-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.90e-04 | 168 | 46 | 3 | 74dc46738f1d0a448df6c9b8288b515d92697792 | |
| ToppCell | Control|World / group, cell type (main and fine annotations) | 6.90e-04 | 168 | 46 | 3 | a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6 | |
| ToppCell | wk_08-11-Epithelial-Airway_epithelial_progenitor-epi-prox-progenitor-MUC5AC+ASCL1+_intermediate_|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 7.14e-04 | 170 | 46 | 3 | d6e244725b21592c6056b9c443aac090f1eae836 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_D|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 7.26e-04 | 171 | 46 | 3 | 943fbca8a6ac04052a2a85aca7b21a3461cd96f7 | |
| ToppCell | 11.5-Airway-Epithelial-Basal_cell|Airway / Age, Tissue, Lineage and Cell class | 7.39e-04 | 172 | 46 | 3 | 9d4d92e2d16dfc8a394f2641653bb97de20a2530 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Granulocytic|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 7.51e-04 | 173 | 46 | 3 | 9eaec30f9a3655b53ece1b66848201a7f85bbdf5 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 7.51e-04 | 173 | 46 | 3 | b799c06a6a5754668e789f70c0c8bc1508568575 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.64e-04 | 174 | 46 | 3 | d0e3d15731de6c19c232e3aa492c39d8151cf4ed | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 7.76e-04 | 175 | 46 | 3 | f0c2eb82e17e8aec2cfa5d83169178f409cc1abc | |
| ToppCell | P03-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.76e-04 | 175 | 46 | 3 | 282f09bbdfa70d93b3f66591dcfb84c5ee0268c7 | |
| Drug | Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; PC3; HT_HG-U133A | 2.42e-06 | 193 | 46 | 6 | 3708_UP | |
| Drug | NS-398; Down 200; 10uM; PC3; HT_HG-U133A | 2.57e-06 | 195 | 46 | 6 | 6892_DN | |
| Drug | Ethoxyquin [91-53-2]; Down 200; 18.4uM; PC3; HT_HG-U133A | 2.81e-06 | 198 | 46 | 6 | 3764_DN | |
| Drug | L(-)-vesamicol hydrochloride [112709-59-8]; Up 200; 13.6uM; HL60; HT_HG-U133A | 2.89e-06 | 199 | 46 | 6 | 3118_UP | |
| Drug | Isocaffeine | 3.99e-06 | 2 | 46 | 2 | CID000001326 | |
| Drug | adenophostin B | 3.99e-06 | 2 | 46 | 2 | CID000656722 | |
| Drug | benzene 1,2,4-trisphosphate | 3.99e-06 | 2 | 46 | 2 | CID000192376 | |
| Drug | 5-deoxy-5-fluoro-myo-inositol | 1.20e-05 | 3 | 46 | 2 | CID000195110 | |
| Drug | CHEBI:697555 | 2.39e-05 | 4 | 46 | 2 | CID009578246 | |
| Drug | Bcp-7 | 2.39e-05 | 4 | 46 | 2 | CID009589384 | |
| Drug | Protoveratrine A [143-57-7]; Down 200; 5uM; MCF7; HT_HG-U133A | 3.89e-05 | 189 | 46 | 5 | 2800_DN | |
| Drug | 17-DMAG; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA | 4.09e-05 | 191 | 46 | 5 | 993_UP | |
| Drug | Propantheline bromide [50-34-0]; Up 200; 9uM; MCF7; HT_HG-U133A | 4.40e-05 | 194 | 46 | 5 | 4798_UP | |
| Drug | Flecainide acetate [54143-56-5]; Up 200; 8.4uM; PC3; HT_HG-U133A | 4.51e-05 | 195 | 46 | 5 | 4318_UP | |
| Drug | Cloperastine hydrochloride [14984-68-0]; Down 200; 11uM; MCF7; HT_HG-U133A | 4.51e-05 | 195 | 46 | 5 | 3408_DN | |
| Drug | Methotrexate [59-05-2]; Up 200; 8.8uM; PC3; HT_HG-U133A | 4.62e-05 | 196 | 46 | 5 | 6318_UP | |
| Drug | Harmalol hydrochloride dihydrate [6028-07-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 4.74e-05 | 197 | 46 | 5 | 5495_UP | |
| Drug | Tiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 4.74e-05 | 197 | 46 | 5 | 7011_DN | |
| Drug | Talampicillin hydrochloride [39878-70-1]; Down 200; 7.8uM; MCF7; HT_HG-U133A | 4.74e-05 | 197 | 46 | 5 | 3515_DN | |
| Drug | Naloxone hydrochloride [357-08-4]; Down 200; 11uM; MCF7; HT_HG-U133A | 4.85e-05 | 198 | 46 | 5 | 1506_DN | |
| Drug | (S)-(-)-Atenolol [93379-54-5]; Up 200; 15uM; HL60; HT_HG-U133A | 4.85e-05 | 198 | 46 | 5 | 3067_UP | |
| Drug | Bethanechol chloride [590-63-6]; Down 200; 20.4uM; MCF7; HT_HG-U133A | 4.85e-05 | 198 | 46 | 5 | 3537_DN | |
| Drug | Nabumetone [42924-53-8]; Up 200; 17.6uM; PC3; HT_HG-U133A | 4.85e-05 | 198 | 46 | 5 | 6327_UP | |
| Drug | Flucytosine [2022-85-7]; Up 200; 31uM; HL60; HT_HG-U133A | 4.97e-05 | 199 | 46 | 5 | 3073_UP | |
| Drug | pioglitazone HCl; Down 200; 10uM; MCF7; HT_HG-U133A | 4.97e-05 | 199 | 46 | 5 | 5925_DN | |
| Drug | retinoic acid; Up 200; 1uM; PC3; HG-U133A | 4.97e-05 | 199 | 46 | 5 | 447_UP | |
| Drug | Fluphenazine dihydrochloride [146-56-5]; Up 200; 7.8uM; MCF7; HT_HG-U133A | 4.97e-05 | 199 | 46 | 5 | 7234_UP | |
| Drug | AC1Q7BER | 5.96e-05 | 6 | 46 | 2 | CID000005702 | |
| Drug | 3-F-InsP3 | 8.33e-05 | 7 | 46 | 2 | CID003035756 | |
| Drug | Br2BAPTA | 8.33e-05 | 7 | 46 | 2 | CID003081001 | |
| Drug | [[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate | 8.33e-05 | 7 | 46 | 2 | CID009547999 | |
| Drug | 9 mM of H | 1.11e-04 | 8 | 46 | 2 | CID000130464 | |
| Drug | 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid | 1.11e-04 | 8 | 46 | 2 | ctd:C064545 | |
| Drug | basic copper carbonate | 1.11e-04 | 8 | 46 | 2 | CID000025503 | |
| Drug | Ns 004 | 1.11e-04 | 8 | 46 | 2 | CID000162750 | |
| Drug | F2 g | 1.11e-04 | 8 | 46 | 2 | CID006857713 | |
| Drug | clausenamide | 1.78e-04 | 10 | 46 | 2 | CID000128412 | |
| Drug | UTP-NA | 1.91e-04 | 420 | 46 | 6 | CID000001181 | |
| Drug | R 478 | 2.17e-04 | 11 | 46 | 2 | CID000084223 | |
| Drug | 8-amino-cADPR | 2.17e-04 | 11 | 46 | 2 | CID003081323 | |
| Drug | 4-hydroxyretinoic acid | 2.60e-04 | 12 | 46 | 2 | ctd:C019429 | |
| Drug | strontium | 3.53e-04 | 68 | 46 | 3 | CID000104798 | |
| Drug | AC1NQGJV | 3.53e-04 | 68 | 46 | 3 | CID005195973 | |
| Drug | Clenbuterol hydrochloride [21898-19-1]; Up 200; 12.8uM; PC3; HT_HG-U133A | 3.67e-04 | 168 | 46 | 4 | 4671_UP | |
| Drug | lavendustin A | 3.92e-04 | 171 | 46 | 4 | CID000003894 | |
| Drug | AC1L8KRN | 4.12e-04 | 15 | 46 | 2 | CID000403109 | |
| Drug | Gvapspat amide | 4.12e-04 | 15 | 46 | 2 | CID000125015 | |
| Drug | (-)-Isoproterenol hydrochloride [5984-95-2]; Up 200; 16.2uM; PC3; HT_HG-U133A | 4.47e-04 | 177 | 46 | 4 | 4495_UP | |
| Drug | ethosuximide | 4.53e-04 | 74 | 46 | 3 | CID000003291 | |
| Drug | Tribenoside [10310-32-4]; Up 200; 8.4uM; HL60; HT_HG-U133A | 5.17e-04 | 184 | 46 | 4 | 2946_UP | |
| Drug | troglitazone; Down 200; 10uM; HL60; HT_HG-U133A | 5.72e-04 | 189 | 46 | 4 | 2692_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A | 5.95e-04 | 191 | 46 | 4 | 2137_UP | |
| Drug | PNU-0293363 [326823-19-2]; Up 200; 10uM; MCF7; HT_HG-U133A | 6.06e-04 | 192 | 46 | 4 | 6573_UP | |
| Drug | Dextromethorphan hydrobromide monohydrate [6700-34-1]; Down 200; 10.8uM; MCF7; HT_HG-U133A | 6.06e-04 | 192 | 46 | 4 | 5401_DN | |
| Drug | Methantheline bromide [53-46-3]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 6.06e-04 | 192 | 46 | 4 | 6254_DN | |
| Drug | wortmannin from Penicillium funiculosum; Down 200; 0.01uM; HL60; HT_HG-U133A | 6.06e-04 | 192 | 46 | 4 | 2703_DN | |
| Drug | Naphazoline hydrochloride [550-99-2]; Down 200; 16.2uM; PC3; HT_HG-U133A | 6.18e-04 | 193 | 46 | 4 | 6604_DN | |
| Drug | Isotretinoin [4759-48-2]; Up 200; 13.4uM; PC3; HT_HG-U133A | 6.18e-04 | 193 | 46 | 4 | 7315_UP | |
| Drug | Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; PC3; HT_HG-U133A | 6.18e-04 | 193 | 46 | 4 | 4338_DN | |
| Drug | Thiamphenicol [15318-45-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 6.18e-04 | 193 | 46 | 4 | 7033_DN | |
| Drug | 0297417-0002B [362658-29-5]; Down 200; 10uM; PC3; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 6895_DN | |
| Drug | Promethazine hydrochloride [58-33-3]; Up 200; 12.4uM; HL60; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 3100_UP | |
| Drug | Iodixanol [92339-11-2]; Down 200; 2.6uM; MCF7; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 4848_DN | |
| Drug | STOCK1N-35215; Down 200; 10uM; PC3; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 6380_DN | |
| Drug | Pyrilamine maleate [59-33-6]; Down 200; 10uM; MCF7; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 3184_DN | |
| Drug | estradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 7000_UP | |
| Drug | Clotrimazole [23593-75-1]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 6.30e-04 | 194 | 46 | 4 | 3166_DN | |
| Drug | Medrysone [2668-66-8]; Down 200; 11.6uM; PC3; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 3705_DN | |
| Drug | Securinine [5610-40-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 3470_DN | |
| Drug | Calycanthine [595-05-1]; Down 200; 11.6uM; PC3; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 5744_DN | |
| Drug | Ticlopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 4155_DN | |
| Drug | Fluvastatin sodium salt [93957-55-2]; Up 200; 9.2uM; PC3; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 6691_UP | |
| Drug | PHA-00665752 [477575-56-7]; Down 200; 10uM; MCF7; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 6578_DN | |
| Drug | Cefamandole sodium salt [30034-03-8]; Down 200; 8.2uM; PC3; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 7394_DN | |
| Drug | DAPH; Down 200; 10uM; PC3; HG-U133A | 6.43e-04 | 195 | 46 | 4 | 578_DN | |
| Drug | Halofantrine hydrochloride [36167-63-2]; Up 200; 7.4uM; MCF7; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 7469_UP | |
| Drug | Molindone hydrochloride [15622-65-8]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 4784_DN | |
| Drug | Crotamiton [483-63-6]; Down 200; 19.6uM; HL60; HT_HG-U133A | 6.43e-04 | 195 | 46 | 4 | 3050_DN | |
| Drug | Methoxamine hydrochloride [61-16-5]; Down 200; 16.2uM; HL60; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 2488_DN | |
| Drug | Riluzole hydrochloride; Down 200; 14.8uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 4689_DN | |
| Drug | (d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 2818_DN | |
| Drug | radicicol; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 5947_DN | |
| Drug | Resveratrol [501-36-0]; Up 200; 17.6uM; PC3; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 5084_UP | |
| Drug | Orphenadrine hydrochloride [341-69-5]; Down 200; 13uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 2318_DN | |
| Drug | wortmannin from Penicillium funiculosum; Down 200; 0.01uM; PC3; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 4467_DN | |
| Drug | Sulfaguanidine [57-67-0]; Up 200; 18.6uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 1495_UP | |
| Drug | Retrorsine [480-54-6]; Down 200; 11.4uM; PC3; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 6601_DN | |
| Drug | Demecarium bromide [56-94-0]; Down 200; 5.6uM; PC3; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 5795_DN | |
| Drug | (+/-)-blebbistatin; Down 200; 17uM; MCF7; HT_HG-U133A_EA | 6.55e-04 | 196 | 46 | 4 | 837_DN | |
| Drug | Cetirizine dihydrochloride [83881-52-1]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 4815_DN | |
| Drug | Lovastatin [75330-75-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 4978_DN | |
| Drug | Antimycin A [1397-94-0]; Up 200; 7.2uM; PC3; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 2098_UP | |
| Drug | prochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A | 6.55e-04 | 196 | 46 | 4 | 4439_DN | |
| Drug | Cefaclor [70356-03-5]; Down 200; 10.4uM; HL60; HT_HG-U133A | 6.68e-04 | 197 | 46 | 4 | 2483_DN | |
| Drug | AH23848 hemicalcium salt hydrate; Up 200; 1uM; MCF7; HT_HG-U133A | 6.68e-04 | 197 | 46 | 4 | 6890_UP | |
| Drug | rofecoxib; Down 200; 10uM; HL60; HG-U133A | 6.68e-04 | 197 | 46 | 4 | 371_DN | |
| Drug | Flurandrenolide [1524-88-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 6.68e-04 | 197 | 46 | 4 | 4702_DN | |
| Drug | Fenoprofen calcium salt dihydrate [53746-45-5]; Up 200; 7.2uM; MCF7; HT_HG-U133A | 6.68e-04 | 197 | 46 | 4 | 3412_UP | |
| Drug | Rolipram [61413-54-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 6.68e-04 | 197 | 46 | 4 | 6449_UP | |
| Drug | Moxonidine [75438-57-2]; Down 200; 16.6uM; PC3; HT_HG-U133A | 6.68e-04 | 197 | 46 | 4 | 4084_DN | |
| Disease | dry eye syndrome (is_implicated_in) | 1.36e-05 | 4 | 45 | 2 | DOID:10140 (is_implicated_in) | |
| Disease | common bile duct neoplasm (is_marker_for) | 6.33e-05 | 8 | 45 | 2 | DOID:4608 (is_marker_for) | |
| Disease | dry eye syndrome (is_marker_for) | 1.02e-04 | 10 | 45 | 2 | DOID:10140 (is_marker_for) | |
| Disease | allergic rhinitis (biomarker_via_orthology) | 1.02e-04 | 10 | 45 | 2 | DOID:4481 (biomarker_via_orthology) | |
| Disease | autosomal dominant cerebellar ataxia (implicated_via_orthology) | 1.49e-04 | 12 | 45 | 2 | DOID:1441 (implicated_via_orthology) | |
| Disease | Charcot-Marie-Tooth disease (is_implicated_in) | 1.49e-04 | 12 | 45 | 2 | DOID:10595 (is_implicated_in) | |
| Disease | otitis media (biomarker_via_orthology) | 3.05e-04 | 17 | 45 | 2 | DOID:10754 (biomarker_via_orthology) | |
| Disease | sphingosine 1-phosphate measurement | 3.43e-04 | 18 | 45 | 2 | EFO_0800185 | |
| Disease | pancreatic cancer (is_marker_for) | 4.98e-04 | 101 | 45 | 3 | DOID:1793 (is_marker_for) | |
| Disease | asthma (is_marker_for) | 9.46e-04 | 126 | 45 | 3 | DOID:2841 (is_marker_for) | |
| Disease | rhinitis (is_marker_for) | 2.26e-03 | 46 | 45 | 2 | DOID:4483 (is_marker_for) | |
| Disease | unipolar depression, sex interaction measurement | 2.77e-03 | 51 | 45 | 2 | EFO_0003761, EFO_0008343 | |
| Disease | systemic scleroderma (is_marker_for) | 2.98e-03 | 53 | 45 | 2 | DOID:418 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YIKCNISDVQCGRIQ | 541 | Q9UKF5 | |
| VAVNNCIRQLSYCKN | 441 | Q92870 | |
| NCQYGVLTKPQLQQC | 751 | A4D0V7 | |
| SQGQCVYRGKVCNLV | 291 | P45844 | |
| QQNPRLCKSYGTCVN | 121 | P48960 | |
| YQNLLNVSCCELGIK | 36 | Q53H64 | |
| AIVVNCYLIGQCGQL | 816 | Q9HCE9 | |
| NCIINKVTRNRCQYC | 131 | P13631 | |
| FLRCQNNKTNYNLVC | 1891 | Q14573 | |
| VCGRYLQQQLDAANC | 121 | Q0D2K2 | |
| NCCKVGASNYLQQVV | 226 | Q8NEZ5 | |
| ANCQYGCDVVKGQIR | 136 | Q6UXI9 | |
| LRCQNNKTNYNLVCE | 1996 | Q14643 | |
| YCRNVLKGCLANQAD | 271 | P35052 | |
| LAVCQCRRKNYGQLD | 1181 | P15941 | |
| CCQAYNLIRKQTNLF | 1316 | O00443 | |
| IVNCQVYGRNALNLK | 316 | Q05C16 | |
| QASGLCYNYQIRVQC | 1461 | P98088 | |
| TNCELKVCFQYLNRG | 331 | Q9Y2J8 | |
| NNYVQGHCRKICRVN | 26 | Q9H1M4 | |
| LILGCAVNCEQKQEY | 121 | Q86VS8 | |
| CKVANYCRQVQQLLG | 561 | Q9Y3T9 | |
| YCRQVQQLLGKVQEN | 566 | Q9Y3T9 | |
| GQALCSLQCYRINLQ | 326 | Q9C086 | |
| VIGAYKQACQKLNCR | 76 | O75864 | |
| CNKKVIDQQNGLYRC | 486 | P27694 | |
| QLYREKVNALQAQVC | 341 | Q9BXL6 | |
| CVRLFKQEGTCYQQA | 146 | Q99741 | |
| LYNQQVGDCCIIRVS | 791 | Q12967 | |
| LQQTCYNLQGGFKCI | 301 | Q9UBX5 | |
| KCGAQRVNNNLQVIC | 336 | Q0P6D2 | |
| YQLLVNSKRQCLECG | 71 | Q9BV36 | |
| CNKCLEGNFYLRQNN | 826 | O75445 | |
| VQLCYANVNGSCVKI | 11 | Q96RI8 | |
| NCSCVEVIGLQNKNY | 456 | G3V0H7 | |
| IVNKYQGLGVNQCDR | 46 | Q96E52 | |
| CKVQKGGYNRINQCL | 121 | Q3SXZ3 | |
| CNQCGRAFSQKQYLI | 166 | Q3ZCT1 | |
| VLLVLENNNNYKCCQ | 66 | Q96CE8 | |
| NAKNCVLLGNICYNC | 56 | Q8WW36 | |
| KYNQIRCLCQRGAEV | 186 | P27708 | |
| PYGCNQCQKLFRNIA | 426 | Q86UD4 | |
| YQQNQASCGKRAIIL | 51 | P78423 | |
| QYDLCIHAQNGRKCQ | 756 | Q9UGR2 | |
| RGQRTNAQKYCQPCT | 36 | Q9P055 | |
| CINYCNEKLQQLFIQ | 411 | B0I1T2 | |
| CVRNLVQKYCRGITA | 821 | Q8N1T3 |